Merck & Company found using ticker (MRK) have now 23 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 135 and 100 calculating the mean target price we have 116.26. With the stocks previous close at 111.07 this would indicate that there is a potential upside of 4.7%. The 50 day moving average now sits at 107.47 and the 200 moving average now moves to 93.96. The company has a market cap of $283,382m. Find out more information at: https://www.merck.com
The potential market cap would be $296,623m based on the market concensus.
Merck & Co. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences to jointly develop and commercialize long-acting treatments in HIV. Merck & Co. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
